In vitro and in vivo investigation of cardiotoxicity associated with anticancer proteasome inhibitors and their combination with anthracycline.
Sign Up to like & getrecommendations! Published in 2019 at "Clinical science"
DOI: 10.1042/cs20190139
Abstract: Although proteasome inhibitors (PIs) are modern targeted anticancer drugs, they have been associated with a certain risk of cardiotoxicity and heart failure (HF). Recently, PIs have been combined with anthracyclines to further boost their anticancer… read more here.
Keywords: proteasome inhibitors; investigation cardiotoxicity; vitro vivo; vivo investigation ... See more keywords